|
시장보고서
상품코드
2078284
항생제 시장 : 약제 클래스별, 투여 경로별, 적응증별, 유통 채널별, 지역별Antimicrobial Therapeutics Market, By Drug Class, By Route of Administration, By Disease Indication, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
항균 치료제 시장은 2026년에 1,300억 2,000만 달러, 2033년까지 1,929억 3,000만 달러에 이를 것으로 예상됩니다. 또한, 2026-2033년 CAGR 5.8%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 1,300억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 5.80% | 2033년 시장 규모 예측 : | 1,929억 3,000만 달러 |
항균 치료제란, 사람이나 동물의 체내에서 세균을 사멸시키거나 그 증식을 억제하는 의약품을 말합니다. 폐렴이나 혈류 감염증(BSI) 등 중증 감염증의 치료에 자주 사용됩니다. 항균 치료제는 정제, 태블릿, 액제 등의 형태로 경구 복용할 수 있습니다. 또한, 더 심각한 감염증의 경우에는 주사나 정맥 주사(IV)도 시행됩니다. 또한 크림, 스프레이, 연고 형태로 피부에 바를 수도 있습니다. 항생제를 잘못 사용하면 심각한 부작용을 일으키거나 내성 미생물이 발생할 우려가 있습니다. 이러한 내성으로 인해, 같은 약이나 해당 감염증에 효과적인 다른 약조차도 치료가 어려워집니다. 항균 치료제는 세균, 바이러스, 진균, 기생충 등의 미생물에 의해 유발되는 감염증의 치료에 사용되는 의약품입니다. 이러한 치료제는 미생물을 사멸시키거나 그 증식을 억제함으로써 효과를 발휘합니다. 그러나 이러한 약물의 오용이나 과다 사용으로 인해 항생제 내성이 발생하고 있으며, 이는 전 세계 보건에 있어 중대한 우려 사항이 되고 있습니다. 감염병의 확산, 신약 개발, 그리고 항생제 내성에 대한 인식 제고로 인해 전 세계 항생제 시장은 성장할 것으로 예측됩니다.
시장 역학:
규제 당국의 제품 승인 증가가 예측 기간 동안 시장 성장을 견인할 것으로 전망됩니다. 예를 들어, 제약회사인 Zydus Lifesciences는 특정 유형의 진균 감염증이나 효모 감염증 치료에 사용되는 항진균제 ‘Micafungin'에 대해 미국 식품의약국(FDA)으로부터 판매 최종 승인을 획득했다고 발표했습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 항균 치료제 시장의 주요 기업 프로파일을 소개했습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- "세계의 항균 치료제 시장” 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 항균 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 원활하게 의사결정을 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 항생제 시장 : 약제 클래스별, 2021년-2033년
제5장 항생제 시장 : 투여 경로별, 2021년-2033년
제6장 항생제 시장 : 질환 적응증별, 2021년-2033년
제7장 항생제 시장 : 유통 채널별, 2021년-2033년
제8장 항생제 시장 : 지역별, 2021년-2033년
제9장 경쟁 구도
제10장 섹션
LSH 26.07.10Antimicrobial Therapeutics Market is estimated to be valued at USD 130.02 Bn in 2026 and is expected to reach USD 192.93 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 130.02 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.80% | 2033 Value Projection: | USD 192.93 Bn |
Antimicrobial therapeutics are medicines that kill or make it harder for bacteria to grow and multiply in people or animals. They are often used to treat serious infections, such as pneumonia or bloodstream infections (BSIs). Antibiotics can be taken by mouth in the form of pills, tablets, or liquids. They can also be injected or given directly into the bloodstream (IV) for more severe infections. They can also be applied to the skin as a cream, spray, or ointment. When used incorrectly, antibiotics can cause serious side effects and lead to resistant microorganisms. This resistance makes it harder to treat infections with the same medicine or even other medicines that are effective against them. Antimicrobial therapeutics are medications used to treat infections caused by microorganisms, including bacteria, viruses, fungi, and parasites. These therapeutics work by either killing the microorganisms or inhibiting their growth. However, the misuse and overuse of these drugs have led to the emergence of antimicrobial resistance, which is a significant global health concern. The global antimicrobial therapeutics market is expected to grow due to the increasing prevalence of infectious diseases, the development of new drugs, and the growing awareness of antimicrobial resistance.
Market Dynamics:
Increasing product approval by regulatory bodies is expected to drive the growth of the market over the forecast period. For instance, Zydus Lifesciences, a pharmaceutical company, announced that it had received final approval from the U.S. Food and Drug Administration (FDA) to market its antifungal medicine Micafungin, which is used to treat certain types of fungal or yeast infections.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global antimicrobial therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche AG, AstraZeneca plc, Sanofi SA, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., AbbVie Inc., Allergan plc, Mylan N.V. and Alembic Pharmaceuticals Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global antimicrobial therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antimicrobial therapeutics market
Detailed Segmentation:
- Global Antimicrobial Therapeutics Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Antibacterials
- Antivirals
- Antifungals
- Antiparasitics
- Global Antimicrobial Therapeutics Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral
- Topical
- Injectable
- Others
- Global Antimicrobial Therapeutics Market, By Disease Indication (Revenue, USD Bn, 2021 - 2033)
- Respiratory Infections
- Urinary Tract Infections (UTIs)
- Skin and Soft Tissue Infections
- Sexually Transmitted Infections (STIs)
- Gastrointestinal Infections
- Central Nervous System Infections
- Others
- Global Antimicrobial Therapeutics Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profile:
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis AG
- F. Hoffmann-La Roche AG
- AstraZeneca plc
- Sanofi SA
- Bayer AG
- Bristol Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences, Inc.
- AbbVie Inc.
- Allergan plc
- Mylan N.V.
- Alembic Pharmaceuticals Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Antimicrobial Therapeutics, By Drug Class
- Market Antimicrobial Therapeutics, By Route of Administration
- Market Antimicrobial Therapeutics, By Disease Indication
- Market Antimicrobial Therapeutics, By Distribution Channel
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Antimicrobial Therapeutics Market , By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Antibacterials
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Antifungals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Antiparasitics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Antimicrobial Therapeutics Market , By Route of Administration, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Antimicrobial Therapeutics Market , By Disease Indication, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Respiratory Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Urinary Tract Infections (UTIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Skin and Soft Tissue Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Sexually Transmitted Infections (STIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Gastrointestinal Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Central Nervous System Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
7. Antimicrobial Therapeutics Market , By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
8. Antimicrobial Therapeutics Market , By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022-2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn )
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn )
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn )
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country,2021 - 2033, (US$ Bn )
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 - 2033, (US$ Bn )
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 - 2033, (US$ Bn )
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi SA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allergan plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
